25 stories
Robert F. Kennedy Jr. has been the single most-watched federal voice on peptides since taking over HHS. The throughline has been a more permissive posture toward research peptides and compounding, paired with skepticism of GLP-1s as a public-health response to obesity.
The most consequential reporting came from ProPublica: RFK Jr. is preparing to reverse the FDA's 2023 effective ban on 19 injectable peptides from compounding pharmacies, prompting public pushback from former FDA officials. Smaller signals followed — softer language in PCAC meetings, slowed enforcement on certain compounding actions, and reframed messaging around dietary supplements and peptide therapy clinics.
The FDA's April 30 proposal to exclude branded GLP-1 actives from the 503B bulks list cuts the other way. Stories here cover the policy moves, the public statements, and the gap between the two.
The FDA held a public meeting at the Natural Products Association's request to discuss broadening supplement criteria to include peptides. FDA official Kyle Diamantas emphasized 'cutting red tape' under the Kennedy-era HHS stance.
The Guardian editorial board criticizes RFK Jr.'s plan to open up ~14 injectable peptides, arguing the MAHA agenda replaces the precautionary principle with 'do your own research' rhetoric benefiting wellness profiteers.
The FDA held a public meeting to discuss broadening supplement ingredient criteria to include peptides, probiotics, and other substances. This is the first such meeting since RFK Jr. became HHS Secretary.
Physician William Meller describes treating a patient in anaphylaxis after self-injecting online peptides, and critiques RFK Jr.'s plan to move ~14 compounds off the FDA restricted list.
Report examining viral social media claims about peptides promising DNA repair, nerve relief, and wound healing, referencing RFK Jr.'s Joe Rogan appearance supporting peptide access.
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.
The Washington Post editorial board published a sharp critique of Health Secretary Kennedy, arguing that his insistence on rigorous evidence for vaccines while simultaneously pushing the FDA to deregulate peptides with minimal human safety data represents a dangerous double standard in public health policy.